- Mendus presenterar framsteg med NK-cellsprogrammet på Innate Killer Summit
- Mendus to present NK cell program progress at the Innate Killer Summit
- Mendus erhåller avsiktsförklaringar från större ägare och styrelse samt bolagsledning avseende nyttjande av teckningsoptioner av serie TO3
- Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3
- The exercise period for warrants of series TO3 commences today
- Nyttjandeperioden för teckningsoptioner av serie TO3 inleds idag
- Mendus ger verksamhetsuppdatering och presenterar utsikter för vididencel-programmet
- Mendus provides business update and outlook for vididencel program
- Mendus to participate in upcoming industry conferences
- Mendus medverkar på flera branschkonferenser
More ▼
Key statistics
As of last trade, Mendus AB (publ) (IMMU:STO) traded at 9.80, 63.33% above the 52 week low of 6.00 set on Aug 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.92 |
---|---|
High | 9.99 |
Low | 9.59 |
Bid | 9.80 |
Offer | 9.82 |
Previous close | 9.93 |
Average volume | 97.57k |
---|---|
Shares outstanding | 1.01bn |
Free float | 464.72m |
P/E (TTM) | -- |
Market cap | 510.65m SEK |
EPS (TTM) | -0.1573 SEK |
Data delayed at least 15 minutes, as of Jun 07 2024 12:32 BST.
More ▼